TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05362435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity-based wellness programs
Description: Each MKS+ program has 20-25 participants and consists of the following: 12 Week INTENSE PHASE: 1) pre-program information and orientation session, and data collection/testing; 2) core weekly programming with the following three components: a) 45-60 minute exercise class, b) 15-20 minute nutrition and wellness education, and c) 15-30 minute sharing circle; 3) end of program celebration; 4) urban poling sessions; 5) introduction to local healthcare providers as identified as relevant for the group; 6) ongoing online support via private Facebook group; 7) daily pedometer tracking to provide immediate motivational feedback to participants. 6-12 Week FOLLOW-UP PHASE: 1) Program Facilitator contacts participants weekly to encourage healthy activities, address concerns as needed, and record weekly step counts; 2) encourages continued engagement in private Facebook group; 3) 15-30 minute nutrition and wellness education, and c) 15-45 minute sharing circle.
Study: NCT06244654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Quest 2 VR virtual reality glasses and wired over-ear headphones
Description: After the VR group comes to the preoperative area and is evaluated, they will be asked to wear VR glasses and headphones. VR glasses and headphones were worn on the patient during peripheral nerve block applications and the operation. At the end of the operation, the VR glasses and headphones were removed and they were taken to the postoperative recovery room.

Intervention type: OTHER
Group type: OTHER
Intervention: No VR
Description: After evaluation of the patients taken to the preoperative area, routine peripheral nerve block application was performed without the use of VR glasses. VR glasses were not worn during the operation, as is the routine protocol. At the end of the surgery, they were taken to the postoperative recovery room.
Study: NCT06320171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive neuromodulation
Description: Direct stimulation of the autonomic nervous system was achieved using Program 7 (P7) of the device, with a directional electrode positioned at the level of the C7 spinous process. P7 delivered a biphasic polarity current with oscillatory frequencies ranging from 1.92 to 14.29 Hz and variable intensities between 0.1 and 0.9 mA.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group followed the same procedure, except that no current was applied during their 20-minute session.
Study: NCT06555068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-6209 in Combination with Fulvestrant
Description: HRS-6209 in Combination with Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-6209 in Combination with HRS-1358
Description: HRS-6209 in Combination with HRS-1358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-6209 in Combination with Letrozole
Description: HRS-6209 in Combination with Letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-6209 in Combination with HRS-8080
Description: HRS-6209 in Combination with HRS-8080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-6209 in Combination with HRS-1358
Description: HRS-6209 in Combination with HRS-1358
Study: NCT05550038

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Compression ultrasound
Description: Patients receive a 3-point compression ultrasound performed by the general practitioner to look for proximal deep vein thrombosis.
Study: NCT06576128

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: In additional to local anesthesia, 10 ml lidocaine (2%) (Lidon, Onfarma, Turkey ), TAPB will be performed under ultrasound imaging..

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: parenteral local anesthesia
Description: As routine procedure; the cardiologist will palpate the right or left femoral artery under sterile conditions and apply approximately 10 ml lidocaine (2%) to this area as local anesthesia (Lidon, Onfarma, Turkey ). Then, a puncture will be made on the anterior wall of the femoral artery with an 18 G needle . Approximately 3-4 mm skin incision will be made with the number 11 scalpel tip and the Seldinger technique will be continued. 6F femoral sheath to be placed, cardiac The catheterization process will begin.
Study: NCT05552443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone 2.5 mcg/kg
Description: 2.5 mcg/kg intrathecal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone 2.75 mcg/kg
Description: 2.75 mcg/kg intrathecal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone 3 mcg/kg
Description: 3 mcg/kg intrathecal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone 3.25 mcg/kg
Description: 3.25 mcg/kg intrathecal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone 3.5 mcg/kg
Description: 3.5 mcg/kg intrathecal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone 4 mcg/kg
Description: 4 mcg/kg intrathecal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone 4.5 mcg/kg
Description: 4.5 mcg/kg intrathecal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone 5 mcg/kg
Description: 5 mcg/kg intrathecal
Study: NCT06573294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEN1057
Description: Intravenous (IV) infusion
Study: NCT05687890

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of SC0062
Description: Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of SC0062
Description: Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC0062 low dose
Description: Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC0062 medium dose
Description: Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC0062 high dose
Description: Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
Study: NCT06155305

Intervention type: PROCEDURE
Intervention: Biopsy
Description: Before initiating neoadjuvant therapy, patients diagnosed with breast cancer undergo a tumor biopsy. The tissue obtained from the biopsy is utilized to establish organoids and conduct drug testing.
Study: NCT05684757

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Advice
Description: Dietary Advice

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Advice
Description: Dietary Advice

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Advice
Description: Dietary Advice
Study: NCT05954286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upamostat
Description: Upamostat is available as a hydrogen sulphate salt (also designated as WX-671.1). WX-671.1 is a white to yellowish powder which is freely soluble in dimethyl sulfoxide and soluble in ethanol. The drug substance is very slightly soluble in water or 0.1 M HCl.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PO)
Description: Oral Capsules
Study: NCT06521775

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 PSMA-11
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT06515691

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M-TAPA block
Description: After the wound closure is completed and the patient is still under genaral anesthesia the M-TAPA block ill be performed. As the patient is in the supine position, the high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Stimuplex® Ultra 360®, Braun, USA) will be placed in a sagittal position at the costochondral junction at the level of the 9th and 10th ribs. After the rib and the external oblique, internal oblique, and transversus abdominis muscles are visualized on USG, using an in-plane technique, the block needle will be advanced and the block location will be confirmed by injecting 5 ml of saline between the internal oblique and transversus abdominis muscles. Once the block location is confirmed, 30 ml of 0.25% bupivacaine (Buvicaine ®) will be applied on each side. The total volume will be 60 ml.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative pain management
Description: ibuprofen 400mg (Ibuprofen-PF®) intravenous (IV), and tramadol (Contramal®) 100 mg IV will be administered to all patients 20 minutes before wound closure. After surgery, Ibuprofen 400 mg will be given three times a day. A patient-controlled analgesia (PCA) system containing 10 mcg/ml fentanyl will be provided to all patients without continuous infusion. Patients can administer boluses of 0.35 mcg/kg with a 15-minute lockout period and a maximum dose of 100 mcg per hour. Another anesthesiologist will assess patients after surgery. If the patient's pain score (NRS) is 4 or higher, IV tramadol (Contramal®) 100 mg will be given as a rescue analgesic.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative pain management
Description: ibuprofen 400mg (Ibuprofen-PF®) intravenous (IV), and tramadol (Contramal®) 100 mg IV will be administered to all patients 20 minutes before wound closure. After surgery, Ibuprofen 400 mg will be given three times a day. A patient-controlled analgesia (PCA) system containing 10 mcg/ml fentanyl will be provided to all patients without continuous infusion. Patients can administer boluses of 0.35 mcg/kg with a 15-minute lockout period and a maximum dose of 100 mcg per hour. Another anesthesiologist will assess patients after surgery. If the patient's pain score (NRS) is 4 or higher, IV tramadol (Contramal®) 100 mg will be given as a rescue analgesic.
Study: NCT06307886

Intervention type: PROCEDURE
Intervention: Patients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy With manipulator
Description: patients who underwent laparoscopic hysterectomy with using uterine manipulator

Intervention type: PROCEDURE
Intervention: lPatients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy without uterine manipulator
Description: patients who underwent laparoscopic hysterectomy without using uterine manipulator
Study: NCT05102097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warm-up
Description: Participants will walk on treadmill at a speed of 1.7 mile per hour (MPH) and 0 inclination each session for 6weeks 3 times in a week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Main exercise
Description: Participants will walk on a treadmill with a starting speed of 1.7 mile per hour with inclination of 1 to 4% starting with 1% and increased by 1% each week until 4 weeks and at week 5 and 6 speed will be increased to 5mile per hour starting from 1.7mile per hour and increased by 0.5 mile per hour each 1minute while inclination will be increased to 5% in week 5 and 6% in week 6. Main exercise will be perform 3 times in a week for 6 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cool down
Description: Participants will walk on treadmill at the speed of 1.7 mile per hour 0 inclination each session for 6 weeks 3 times in a week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants will perform Abdominal hollowing, isometric back extension exercise, bridging exercise, graded active flexion, graded active extension by holding for 5seconds and repeated 10times

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants will perform Abdominal hollowing, isometric back extension exercise, bridging exercise, graded active flexion, graded active extension by holding for 5seconds and repeated 10times
Study: NCT05100628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 800 mg (400 mg suppository twice daily \[BID\]).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 1200 mg daily (600 mg suppository BID).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 1800 mg daily (600 mg suppository thrice daily).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: MTD of the combination of NOX66 and doxorubicin will be determined in the dose-escalation cohort of the study. The selected dose will be administered in combination with Doxorubicin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be given at 75 mg/m\^2 as an intravenous infusion on Day 2 of the 21-day cycle for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be given at 75 mg/m\^2 as an intravenous infusion on Day 2 of the 21-day cycle for up to 6 cycles.
Study: NCT05733611

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP2
Description: Genetically modified herpes simplex type 1 virus
Study: NCT05100628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be given at 75 mg/m\^2 as an intravenous infusion on Day 2 of the 21-day cycle for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be given at 75 mg/m\^2 as an intravenous infusion on Day 2 of the 21-day cycle for up to 6 cycles.
Study: NCT05733611

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP3
Description: Genetically modified herpes simplex type 1 virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: anti-PD-L1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: anti-PD-L1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: anti-VEGF therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: anti-VEGF therapy
Study: NCT06417814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dato-DXd
Description: Dato-DXd will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dato-DXd
Description: Dato-DXd will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered as IV infusion.
Study: NCT05903859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid 500 Milligrams (mg)
Description: Participants in this group will receive 500 mg of probenecid by mouth twice a day for a total of 90 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: probenecid 250 Milligrams (mg)
Description: Participants in this group will receive 250 mg of probenecid by mouth twice a day for a total of 90 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this group will receive a placebo pill by mouth twice a day for a total of 90 days.
Study: NCT05442853

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring
Description: Continuous glucose monitoring involves a wearable device that measures glucose with a sensor that is inserted subcutaneously. The sensor transmits data to receiving device that displays the glucose values.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Point of care glucose monitoring
Description: Point of care glucose monitoring involves use of an external device that can provide glucose readings at a patient's bedside. These devices require a small blood sample from venous, arterial, or capillary fingerstick blood. The blood sample is analyzed by the device and reports a glucose value within 5 minutes. This method of glucose monitoring is a mainstay and standard of care for most hospitals in the United States.
Study: NCT06469164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT331
Description: Vaginal insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT331
Description: Vaginal insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT331
Description: Vaginal insert

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal insert

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal insert
Study: NCT05578651

Intervention type: DEVICE
Intervention: SternaLock XP
Description: Plating system with cable cerclage bands that is used in the stabilization and fixation of fractures of the anterior chest wall, including sternal fixation following sternotomy
Study: NCT04731818

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZB-06
Description: ZB-06 is a polyvinyl alcohol-based film containing 20 mg of human contraceptive antibody (HCA) for topical intravaginal administration.
Study: NCT04790344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational LUX-Dx ICM Implant
Description: All subject will receive an investigational version of the LUX-Dx ICM device.
Study: NCT05324410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-840
Description: Solution for oral administration.
Study: NCT06128252

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taurine
Description: Taurine supplementation in tablets of 1.0 gram of taurine powder. Dosage: 3.0 gram/day. Frequency: 3 time/day.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Serplulimab
Description: Serplulimab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX regimen
Description: Oxaliplatin + capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX regimen
Description: Oxaliplatin + capecitabine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Taurine placebo in tablets of 1.0 gram of starch powder. Dosage: 3.0 gram/day. Frequency: 3 time/day.
Study: NCT06604988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-feedback intervention to promote positive parenting
Description: Each session will focus on three parental behaviours (that support child development) that have appeared clearly, frequently and consistently in the video (PICCOLO score of 2) in any of the 4 dimensions (affection, responsiveness, encouragement, teaching). Other aspects of parental behaviours that have scored 1 or 0 on the PICCOLO will also be considered, to increase their frequency or encourage their appearance. It is to be expected that all the behaviours collected in PICCOLO appear in one or more of the recordings, even if only occasionally. Behaviours that do not appear can be introduced through linking strategies with other behaviours in which parents show strength (for example, if a caregiver tends to name objects a lot, a link can be established between naming and asking the child the name of objects, if questions are behaviour that does not appear in the logs).~In each session, the caregiver is shown video clips that clearly show the positive parenting behaviours.
Study: NCT06605963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPV-06
Description: 6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
Study: NCT06599567

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional therapy
Description: Cold - Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Graded motor imagery
Description: Cold-Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises, graded motor imagery training (body right-left discrimination exercise, imagining the movement and exercising the opposite limb in front of the mirror).
Study: NCT05745558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: The prehabilitation program consists of 4 components:~1. Fitness training led by a physiotherapist. The patients will receive personalized training schedules to perform at home. The training sessions focus on improving aerobic fitness (biking or walking) and muscle strength (specific exercises for the different patient groups) and respiratory exercises aimed to relax.~2. Nutritional counseling led by a dietician. All patients will be offered an intake with a dietician (60 min) to discuss current eating habits and give personalized advices. Based on indication, patients will receive follow-up consults.~3. Smoking cessation counseling led by a trained social worker. For patients that are currently smoking, a social worker will offer counseling sessions to coach the patient in the process of smoking cessation.~4. Psychosocial counseling led by a psychologist. All patients will be offered counselling by a psychologist.
Study: NCT05455788

Intervention type: DRUG
Intervention: Aminoglycoside
Description: injection of sewing ring of prosthetic valve with aminoglycoside
Study: NCT06486090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: #Utviklingsklar
Description: The intervention consists of 1) an e-learning course, 2) a workshop to create plans and practices for injury-prevention, 3) a mid-season meeting